Lido Advisors LLC Lowers Stock Position in Medtronic PLC $MDT

Lido Advisors LLC cut its stake in shares of Medtronic PLC (NYSE:MDT) by 8.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 89,301 shares of the medical technology company’s stock after selling 8,141 shares during the period. Lido Advisors LLC’s holdings in Medtronic were worth $8,573,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in MDT. WCG Wealth Advisors LLC boosted its position in Medtronic by 150.1% during the 4th quarter. WCG Wealth Advisors LLC now owns 67,780 shares of the medical technology company’s stock worth $6,511,000 after purchasing an additional 40,683 shares during the period. Nvest Financial LLC increased its position in shares of Medtronic by 23.1% during the fourth quarter. Nvest Financial LLC now owns 11,071 shares of the medical technology company’s stock worth $1,063,000 after acquiring an additional 2,079 shares during the last quarter. Avestar Capital LLC lifted its position in shares of Medtronic by 3.1% during the fourth quarter. Avestar Capital LLC now owns 8,277 shares of the medical technology company’s stock worth $795,000 after purchasing an additional 251 shares during the last quarter. Phillips Wealth Planners LLC lifted its position in shares of Medtronic by 17.1% during the fourth quarter. Phillips Wealth Planners LLC now owns 11,090 shares of the medical technology company’s stock worth $1,112,000 after purchasing an additional 1,621 shares during the last quarter. Finally, CIBC Asset Management Inc lifted its position in shares of Medtronic by 18.3% during the fourth quarter. CIBC Asset Management Inc now owns 1,072,930 shares of the medical technology company’s stock worth $103,066,000 after purchasing an additional 166,085 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Trading Down 0.3%

Shares of NYSE:MDT opened at $81.66 on Friday. The firm has a fifty day moving average of $81.46 and a two-hundred day moving average of $92.04. The firm has a market capitalization of $104.84 billion, a P/E ratio of 21.89, a price-to-earnings-growth ratio of 2.00 and a beta of 0.58. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The company had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter last year, the business posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities analysts expect that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Investors of record on Friday, June 26th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.5%. The ex-dividend date of this dividend is Friday, June 26th. This is a boost from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s fiscal Q4 results beat revenue expectations and showed continued year-over-year growth, while management signaled confidence in the company’s FY26/FY27 growth outlook and new product platforms. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Positive Sentiment: BTIG upgraded Medtronic to Buy with a $90 target, citing a strong revenue beat and improving organic growth, while other firms such as TD Cowen and RBC reaffirmed bullish ratings. Wall Street May Be Mispricing Medtronic, Analyst Says
• Positive Sentiment: Medtronic expanded its relationship with Retia Medical to distribute the Argos Cardiac Output Monitor across Western Europe, adding to its cardiovascular portfolio and international reach. Retia Medical Expands Distribution of Argos® Cardiac Output Monitor to Western Europe with Medtronic
• Positive Sentiment: Medtronic also announced a higher quarterly dividend, signaling confidence in cash generation and shareholder returns. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Neutral Sentiment: Several brokerages lowered price targets after earnings, but most still kept Buy/Outperform or Hold/Neutral ratings, suggesting a reset in expectations rather than a major change in long-term views. Rothschild & Co Redburn cuts Medtronic price target
• Neutral Sentiment: Analyst roundups highlighted that Wall Street’s average recommendation remains Buy, but those consensus ratings are often viewed as overly optimistic and not always predictive. Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: Medtronic is still dealing with ongoing cardiovascular device recalls tied to potential sterile barrier issues, which could weigh on investor sentiment and create some execution risk. Medtronic Balances Hugo Robotics Expansion With Ongoing Cardiovascular Device Recalls

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on MDT shares. Deutsche Bank Aktiengesellschaft cut their target price on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating on the stock in a report on Thursday. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, April 11th. Royal Bank Of Canada reiterated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research note on Thursday. Rothschild & Co Redburn lowered their price objective on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Weiss Ratings lowered shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 21st. Seventeen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).